Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Ophthalmology

Volumn 122, Issue 9, 2015, Pages 1837-1845

  Gillies, Mark C ^a   Campain, Anna ^a   Barthelmes, Daniel ^a,b   Simpson, Judy M ^c   Arnold, Jennifer J ^d   Guymer, Robyn H ^e   McAllister, Ian L ^f   Essex, Rohan W ^g   Morlet, Nigel ^f   Hunyor, Alex P ^a,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Marsden Eye Specialists   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h Retina Asso   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; FEMALE; FOLLOW UP; GEOGRAPHIC ATROPHY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGISTER; RETINA FOVEA; RETINA NEOVASCULARIZATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETREATMENT; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; REGISTRIES; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84939776608     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.05.010     Document Type: Article

References (17)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
4. D.F. Martin, M.G. Maguire, G.S. Ying, and et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 120 2012 209 210
6. A. Vaze, S. Fraser-Bell, and M. Gillies Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration Acta Ophthalmol 92 2014 e697 e698
7. F. Abedi, S. Wickremasinghe, A.F. Islam, and et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years Retina 34 2014 1531 1538
8. J.E. Grunwald, E. Daniel, J. Huang, and et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 121 2014 150 161
9. S. Rofagha, R.B. Bhisitkul, D.S. Boyer, and et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2013 2292 2299
10. M.C. Gillies, R. Walton, J. Liong, and et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project Retina 34 2014 188 195
11. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity Ophthalmology 121 2014 1092 1101
12. R: A Language and Environment for Statistical Computing, R Development Core Team 2012 R Foundation for Statistical Computing Vienna, Austria
13. W.S. Cleveland, E. Grosse, and W.M. Shyu Local Regression Models. Statistical Models in S 1992 Wadsworth & Brooks/Cole Pacific Grove, CA
14. A. Vaze, S. Fraser-Bell, and M.C. Gillies Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Retina 34 2004 1774 1778
15. D. Barthelmes, R.J. Walton, J.J. Arnold, and et al. Intravitreal therapy in bilateral neovascular age-related macular degeneration Ophthalmology 121 2014 2073 2074
16. D.C. Schmittlein Surprising inferences from unsurprising observations: do conditional expectations really regress to the mean? Am Stat 43 1989 176 183
17. S. Wickremasinghe, F. Abedi, S.S. Sandhu, and R. Guymer Lessons learnt inform our approach to new antivascular endothelial growth factor treatments for neovascular age-related macular degeneration Clin Experiment Ophthalmol 41 2013 723 726